• ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer

  NCT04889924

  RecruitingInterventionalNot ApplicableUpdated Jul 29, 2026
• Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)

  NCT03513614

  Active, not recruitingInterventionalNot ApplicableUpdated May 1, 2026
• Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy

  NCT04109079

  RecruitingInterventionalNot ApplicableUpdated Mar 30, 2026
• Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study

  NCT07546695

  RecruitingObservationalUpdated May 19, 2026
• Nodal Burden and Nodal Recurrence in Patients With Isolated Tumor Cells After Neoadjuvant Chemotherapy Treated With Axillary Dissection or Nodal Radiation: the OPBC-05/EUBREAST-14R/ICARO Study

  NCT06464341

  CompletedObservationalUpdated Jan 20, 2025
• No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy

  NCT06704945

  RecruitingInterventionalPhase 3Updated Jan 28, 2026

ClinicalTrials.gov ID

NCT07140172

Lead Sponsor

University Hospital, Basel, SwitzerlandOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

1,060Estimated

Last Update Posted

Aug 7, 2026Actual

Start Date

Jan 1, 2026Actual

Primary Completion Date

Dec 31, 2029Estimated

Completion Date

Dec 2037Estimated

Official Title

Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery: An International, Randomized Superiority Trial (OPBC-10/ NOAX)

Brief Summary

This trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related Quality of Life (QoL) and occurrence of lymphedema two years after randomization.

Detailed Description

Despite major morbidity, axillary lymph node dissection (ALND) is standard of care in patients with clinically node positive breast cancer (cN+ BC) who undergo upfront surgery, which is frequently indicated in case of luminal biology. Tailored axillary surgery (TAS) was shown to selectively target positive nodes, thereby removing significantly more nodes than sentinel lymph node biopsy (SLNB), but less nodes than ALND. Therefore, it is currently unclear if TAS in combination with axillary radiotherapy (ART) exposes the axilla to less harm compared to ALND. It is hypothesized that patient's quality of life (QoL) and morbidity can be improved by replacing ALND with the combination of TAS and ART in patients undergoing upfront surgery.

The main goal of this trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related QoL and occurrence of lymphedema two years after randomization.

• Breast Cancer

• Axillary lymph node dissection (ALND)
• Axillary radiotherapy (ART)

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria at screening:

• Written informed consent according to ICH/GCP regulations prior to any trial specific procedures.

• Patients ≥ 18 years of age.

• Node-positive breast cancer (histologically or cytologically proven both in primary tumor and in lymph node) American Joint Committee on Cancer/ International Union Against Cancer (AJCC/UICC) stage II-III (all molecular subtypes allowed).

• Node-positivity detected by imaging and non-palpable (iN+) and confirmed by pathology.

• Node-positivity palpable (cN1-3) and confirmed by pathology.

• Occult breast cancer is allowed, if biopsy-proven axillary lymphatic metastasis is present.

• Eligible for primary ALND or SLN procedure and either:

  • Newly diagnosed.
  • Isolated in-breast recurrence or second ipsilateral breast cancer after previous breast conserving surgery and sentinel procedure and at least 3 years disease free and no prior axillary dissection or axillary RT.

• Upfront surgery setting.

• Most suspicious axillary lymph node clipped. (If clipping is not part of the routine, this should be done after consent of the patient as a study procedure.)

• Ability to complete the QoL questionnaires.

• WHO performance status 0-2

• Adequate condition for general anesthesia, breast cancer surgery and radiotherapy.

• Adult patients (≥18 years of age).

• Women of child-bearing potential are using effective contraception (condom, diaphragm, intrauterine device), are not pregnant or lactating and agree not to become pregnant during trial treatment (until end of RT) and thereafter during the time recommended by the guidelines - also for adjuvant systemic therapies. A negative pregnancy test before registration is required for all women of child-bearing potential.

• Men agree not to father a child during trial treatment and for 6 months afterward.

Exclusion criteria at screening:

• Stage IV breast cancer.
• Clinical N3c breast cancer without axillary disease (clinical N3a and clinical N3b are allowed).
• Clinical N2b breast cancer (clinical N2a is allowed).
• Contralateral breast cancer within 3 years.
• Prior axillary surgery (except prior sentinel node procedure in case of in-breast recurrence).
• Prior regional radiotherapy.
• Neoadjuvant treatment with the exception of bridging therapy given for less than 3 months.
• History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from pre-registration with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer.
• Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.

Exclusion criteria at randomization (intraoperatively):

• Absence of clip in the specimen radiography.
• Palpable disease left behind in the axilla after TAS.
• No SLN identified in the axilla.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

University Hospital, Basel, SwitzerlandOTHER

christopher.hager@dornbirn.at